Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 66
- Registration Number
- NCT05642572
- Locations
- 🇺🇸
Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States
🇺🇸Saint Francis Cancer Center, Colorado Springs, Colorado, United States
🇺🇸Illinois CancerCare-Eureka, Eureka, Illinois, United States
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT05629234
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT05546866
- Locations
- 🇨🇳
Research Site, Xi'an, China
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05513664
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳Chongqing Cancer Hospital, Chongqing, China
🇨🇳Southwest Hospital of Army Medical University, Chongqing, China
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
- Conditions
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-19
- Target Recruit Count
- 50
- Registration Number
- NCT05507606
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT05498389
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, United States
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 80
- Registration Number
- NCT05458726
- Locations
- 🇨🇳
Junling Li, Beijing, Beijing, China
Osimertinib for NSCLC With Uncommon EGFR Mutations
- Conditions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT05421936
- Locations
- 🇮🇱
Sheba Medical Centre, Ramat Gan, Israel
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Karen Reckamp, MD, MS
- Target Recruit Count
- 60
- Registration Number
- NCT05401110
- Locations
- 🇺🇸
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC, Torrance, California, United States
🇺🇸Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California, United States
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 680
- Registration Number
- NCT05382728
- Locations
- 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.